



Author index

Volume 119 (1996)

- Andersson, A., see Wiklund, O. 119, 99
Arveiler, D., see Lane, A. 119, 119
Bara, L., see Lane, A. 119, 119
Bauer, J., see Lucas, A. 119, 17
Bétard, C., A.M. Kessling, M. Roy, J. Davignon, Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes sharing a 'null' LDL-receptor gene defect 119, 43
Bondjers, G., see Wiklund, O. 119, 57
Boomsma, D.I., see Hoffer, M.J.V. 119, 159
Borch-Johnsen, K., see Skov Jensen, J. 119, 69
Bravo, E., G. Ortu, R. Rivabene, M.T. Santini, A. Cantafora, Probucol reduces hepatic cholesterol secretion in hyperlipidemic Yoshida rats 119, 223
Bräutigam, C., B. Engelmann, D. Reiss, U. Reinhardt, J. Thiery, W.O. Richter, T. Brosche, Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis 119, 77
Bredie, S.J.H., see Hoffer, M.J.V. 119, 159
Brennan, C., see Jones, R.J. 119, 151
Brosche, T., see Bräutigam, C. 119, 77
Cambien, F., see Lane, A. 119, 119
Cambou, J.P., see Lane, A. 119, 119
Camejo, G., see Wiklund, O. 119, 57
Cantafora, A., see Bravo, E. 119, 223
Cantin, B., see Lamarche, B. 119, 235
Chagpar, A., see Lucas, A. 119, 17
Chung, T.K.H., see Haines, C.J. 119, 215
Collins, P.B., see Jones, R.J. 119, 151
Dagenais, G.R., see Lamarche, B. 119, 235
Dai, E., see Lucas, A. 119, 17
Darley-Usmar, V., see O'Leary, V.J. 119, 169
Davignon, J., see Bétard, C. 119, 43
de Knijff, P., see Hoffer, M.J.V. 119, 159
Demacker, P.N.M., see Hoffer, M.J.V. 119, 159
Després, J.-P., see Lamarche, B. 119, 235
Dobmeyer, J., J. Lohrmann, G. Feussner, Prevalence and association of atherosclerosis at three different arterial sites in patients with type III hyperlipoproteinemia 119, 89
Engelmann, B., see Bräutigam, C. 119, 77
Evans, A., see Lane, A. 119, 119
Fager, G., see Wiklund, O. 119, 99
Feldt-Rasmussen, B., see Skov Jensen, J. 119, 69
Feussner, G., see Dobmeyer, J. 119, 89
Firth, J.C., see Naoumova, R.P. 119, 203
Fleetwood, G., see O'Leary, V.J. 119, 169
Frants, R.R., see Hoffer, M.J.V. 119, 159
Fuller, C.J., S.M. Grundy, E.P. Norkus, I. Jialal, Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers 119, 139
Garbutt, M., see Lucas, A. 119, 17
Gnasso, A., C. Irace, P.L. Mattioli, A. Pujia, Carotid intima-media thickness and coronary heart disease risk factors 119, 7
Green, F., see Lane, A. 119, 119
Grundy, S.M., see Fuller, C.J. 119, 139
Hakamata, H., see Sakai, M. 119, 191
Havekes, L.M., see Hoffer, M.J.V. 119, 159
He, Y., W.C.P. Kwan, U.P. Steinbrecher, Effects of oxidized low density lipoprotein on endothelin secretion by cultured endothelial cells and macrophages 119, 107
Horiuchi, S., see Sakai, M. 119, 191
Hoffer, M.J.V., S.J.H. Bredie, D.I. Boomsma, P.W.A. Reymer, J.J.P. Kastelein, P. de Knijff, P.N.M. Demacker, A.F.H. Stalenhoef, L.M. Havekes, R.R. Frants, The lipoprotein lipase (Asn291 → Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia 119, 159
Hultberg, B., see Wiklund, O. 119, 99
Humphries, S., see Lane, A. 119, 119
Irace, C., see Gnasso, A. 119, 7

- Jensen, G., see Skov Jensen, J. 119, 69
- Haines, C.J., T.K.H. Chung, J.R.L. Masarei, B. Tomlinson, J.T.F. Lau, An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins 119, 215
- Jialal, I., see Fuller, C.J. 119, 139
- Jiang, X.Y., see Lucas, A. 119, 17
- Johnson, A.H., see Jones, R.J. 119, 151
- Jokela, H., see Nikkilä, M. 119, 181
- Jones, R.J., D. Owens, C. Brennan, P.B. Collins, A.H. Johnson, G.H. Tomkin, Increased esterification of cholesterol and transfer of cholesterol ester to apo B-containing lipoproteins in Type 2 diabetes: relationship to serum lipoproteins A-I and A-II 119, 151
- Kang, S.-S., P.W.K. Wong, Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia 119, 135
- Kappagoda, C.T., see Skepper, J.N. 119, 247
- Kastelein, J.J.P., see Hoffer, M.J.V. 119, 159
- Kessling, A.M., see Bétard, C. 119, 43
- Kobori, S., see Sakai, M. 119, 191
- Koivula, T., see Nikkilä, M. 119, 181
- Kwan, W.C.P., see He, Y. 119, 107
- Laippala, P., see Nikkilä, M. 119, 181
- Lamarche, B., J.-P. Després, S. Moorjani, B. Cantin, G.R. Dagenais, P.-J. Lupien, Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study 119, 235
- Lane, A., F. Green, P.Y. Scarabin, V. Nicaud, L. Bara, S. Humphries, A. Evans, G. Luc, J.P. Cambou, D. Arveiler, F. Cambien, Factor VII Arg/Gln₃₅₃ polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTM study 119, 119
- Lau, J.T.F., see Haines, C.J. 119, 215
- Lehtimäki, T., see Nikkilä, M. 119, 181
- Lehtomäki, E., see Nikkilä, M. 119, 181
- Liu, L.-y., see Lucas, A. 119, 17
- Lohrmann, J., see Dobmeyer, J. 119, 89
- Luc, G., see Lane, A. 119, 119
- Lucas, A., W. Yue, X.Y. Jiang, L.-y. Liu, W.-d. Yan, J. Bauer, W. Schneider, J. Tulip, A. Chagpar,
- Lundstam, U., see Wiklund, O. 119, 99
- Lupien, P.-J., see Lamarche, B. 119, 235
- Marais, A.D., see Naoumova, R.P. 119, 203
- Masarei, J.R.L., see Haines, C.J. 119, 215
- Masson, P., see Wiklund, O. 119, 99
- Mattioli, P.L., see Gnasso, A. 119, 7
- Miyazaki, A., see Sakai, M. 119, 191
- Montague, P., see Lucas, A. 119, 17
- Moorjani, S., see Lamarche, B. 119, 235
- Morikawa, W., see Sakai, M. 119, 191
- Mountney, J., see Naoumova, R.P. 119, 203
- Naoumova, R.P., A.D. Marais, J. Mountney, J.C. Firth, N.B. Rendell, G.W. Taylor, G.R. Thompson, Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolemia 119, 203
- Nicaud, V., see Lane, A. 119, 119
- Nikkilä, M., T. Pitkäjärvi, T. Koivula, T. Solakivi, T. Lehtimäki, P. Laippala, H. Jokela, E. Lehtomäki, K. Seppä, Norkus, E.P., see Fuller, C.J. 119, 139
- Nourooz-Zadeh, J., see Wolff, S.P. 119, 261
- O'Leary, V.J., L. Tilling, G. Fleetwood, D. Stone, V. Darley-Usmar, The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy 119, 169
- Ortu, G., see Bravo, E. 119, 223
- Owens, D., see Jones, R.J. 119, 151
- Perk, M., see Lucas, A. 119, 17
- Pitkäjärvi, T., see Nikkilä, M. 119, 181
- Puddey, I.B., Review article Low serum cholesterol and the risk of cerebral haemorrhage 119, 1
- Pujia, A., see Gnasso, A. 119, 7
- Radosavljevic, M., see Lucas, A. 119, 17
- Reinhardt, U., see Bräutigam, C. 119, 77
- Reiss, D., see Bräutigam, C. 119, 77
- Rendell, N.B., see Naoumova, R.P. 119, 203
- Reymer, P.W.A., see Hoffer, M.J.V. 119, 159
- Richter, W.O., see Bräutigam, C. 119, 77
- Rivabene, R., see Bravo, E. 119, 223
- Roy, M., see Bétard, C. 119, 43
- Sakai, M., A. Miyazaki, H. Hakamata, Y. Sugino, Y.-I. Sakamoto, W. Morikawa, S. Kobori, M. Shichiri, S. Horiuchi, Reconstituted high density lipoprotein reduces the capacity of oxidatively modified low density lipoprotein to accumulate cholesterol esters in mouse peritoneal macrophages 119, 191
- Sakamoto, Y.-I., see Sakai, M. 119, 191
- Santini, M.T., see Bravo, E. 119, 223
- Scarabin, P.Y., see Lane, A. 119, 119
- Schneider, W., see Lucas, A. 119, 17
- Seppä, K., see Nikkilä, M. 119, 181
- Shichiri, M., see Sakai, M. 119, 191
- Sillanaukee, P., see Nikkilä, M. 119, 181
- Skepper, J.N., C.T. Kappagoda, The effect of isradipine administration on existing fatty streaks in the cholesterol-fed rabbit: A morphometric study 119, 247
- Skov Jensen, J., K. Borch-Johnsen, G. Jensen, B. Feldt-Rasmussen, Insulin sensitivity in clinically healthy individuals with microalbuminuria 119, 69
- Solakivi, T., see Nikkilä, M. 119, 181
- Stalenhoef, A.F.H., see Hoffer, M.J.V. 119, 159
- Steinbrecher, U.P., see He, Y. 119, 107
- Stone, D., see O'Leary, V.J. 119, 169
- Sugino, Y., see Sakai, M. 119, 191
- Taylor, G.W., see Naoumova, R.P. 119, 203

- Thiery, J., see Bräutigam, C. 119, 77
Thompson, G.R., see Naoumova, R.P. 119, 203
Tilling, L., see O'Leary, V.J. 119, 169
Tomkin, G.H., see Jones, R.J. 119, 151
Tomlinson, B., see Haines, C.J. 119, 215
Tulip, J., see Lucas, A. 119, 17
Wiklund, O., G. Bondjers, I. Wright, G. Camejo, Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs 119, 57
Wiklund, O., G. Fager, A. Andersson, U. Lundstam, P. Masson, B. Hultberg, *N*-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels 119, 99
Wolff, S.P., J. Nourooz-Zadeh, Hypothesis: UK consumption of dietary lipid hydroperoxides — a possible contributory factor to atherosclerosis 119, 261
Wong, P.W.K., see Kang, S.-S. 119, 135
Wright, I., see Wiklund, O. 119, 57
Yan, W.-d., see Lucas, A. 119, 17
Yue, W., see Lucas, A. 119, 17





ELSEVIER

Atherosclerosis 119 (1996) 269–270

atherosclerosis

Subject index

Volume 119 (1996)

- Alcohol **119**, 235
Alpha tocopherol **119**, 77
Apolipoprotein A-II **119**, 151
Apolipoprotein E **119**, 89, 181
Apoprotein A-1 **119**, 151
Ascorbate **119**, 139
Atherosclerosis **119**, 7, 17, 57, 89, 107, 169
Atherosclerotic vascular disease **119**, 69
Atorvastatin **119**, 203
Avian model **119**, 17
- Bile **119**, 223
Blood pressure **119**, 69
Body weight **119**, 69
- Cerebral haemorrhage **119**, 1
Cholesterol **119**, 223, 235, 247
Cholesterol **119**, 159
Cholesterol biosynthesis **119**, 203
Cholesteryl ester transfer protein **119**, 151
Coronary artery disease **119**, 181
Coronary heart disease **119**, 215
Cysteine **119**, 99
- Dietary lipid **119**, 261
Digitonin **119**, 247
Discoidal HDL **119**, 191
Dysbetalipoproteinemia **119**, 89
- Echo-Doppler **119**, 7
ECTIM **119**, 119
Endothelial cells **119**, 107
Endothelin **119**, 107
- Factor VII Arg/Gln₃₅₃ polymorphism **119**, 119
Factor VII coagulant activity **119**, 119
Familial combined hyperlipidaemia **119**, 159
Familial hypercholesterolaemia **119**, 203
Familial hypercholesterolemia **119**, 43
Fatty streak **119**, 247
Foam cell formation **119**, 191
- Free radicals **119**, 139
Genetic defects **119**, 135
- Haplotype **119**, 43
HDL **119**, 77
HDL-C **119**, 235
Homocysteine **119**, 99
Homocystinuria **119**, 135
Hydroperoxides **119**, 261
Hyperhomocyst(e)inemia **119**, 135
Hyperlipidemia **119**, 57, 223
- Inheritance **119**, 135
Insulin sensitivity **119**, 69
Isradipine **119**, 247
- LDL **119**, 139
LDL oxidation **119**, 169
LDL receptor **119**, 43
LDL size **119**, 181
Lecithin:cholesterol acyltransferase **119**, 151
Lipid lowering therapy **119**, 1
Lipids **119**, 69
Lipoprotein **119**, 223
Lipoprotein(a) **119**, 99, 215
Lipoprotein lipase **119**, 159
Lipoproteins **119**, 57, 215
Liver **119**, 223
Low density lipoprotein **119**, 181
LPL(Asn291→Ser) mutation **119**, 159
- Macrophages **119**, 107
Macrophage scavenger receptor(s) **119**, 191
Menopause **119**, 215
Microalbuminuria **119**, 69
MI risk factors **119**, 119
Morphometry **119**, 247
- N-acetylcysteine **119**, 99

- Oxidation 119, 139
Oxidized LDL 119, 107, 191
- Phospholipid transfer 119, 191
Plasma mevalonic acid 119, 203
Plasmenylcholine 119, 77
Plasmenylethanolamine 119, 77
Polyunsaturated fatty acids 119, 77
Pravastatin 119, 203
Probucol 119, 169
Proteoglycans 119, 57
- Rats 119, 223
Red blood cell membranes 119, 77
Regression 119, 247
Restenosis 119, 17
Risk Factors 119, 235
- Serum cholesterol 119, 1
Simvastatin 119, 203
Smoking 119, 139
- Thrombosis risk factors 119, 119
Triglycerides 119, 159, 235
Type 2 diabetes 119, 151
Type III hyperlipoproteinemia 119, 89
- Ultrasound 119, 7
- Vascular disease 119, 135
- Watanabe rabbits 119, 169